ENO2 and neoplasm: A review from 2020 stated that chromogranin, although a sensitive and specific serum marker for low-grade neuroendocrine tumors, has limited use in high-grade NEC, as well as for NSE, because NEC serum tumor markers have low specificity and high variability [32].